Glioma Clinical Trial
Official title:
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
This research is being done to study the safety and utility of 5-aminolevulinic acid (5-ALA)
(also known as Gliolan) for identifying brain tumor tissue during surgery. The goal of this
study is to determine if 5-ALA can differentiate between tumor and normal brain tissue.
Sometimes, during brain surgery, the removal of tumor tissue can be difficult because the
tumor can look like normal brain tissue. Studies in other countries have shown that in some
brain tumors, 5-ALA can make the tumors appear brighter under ultraviolet light. This may
make it easier for doctors to remove as much tumor as safely as possible from your brain.
This study also hopes to see if 5-ALA can find different cell populations within the tumor
that is removed and allow the researchers to better understand brain tumors.
The purpose of this study is to:
- Find out how well 5-ALA can separate normal brain tissue from tumor tissues AND to see
how well 5-ALA can find different cell populations within brain tumors
- Identify the amount of 5-ALA that should be taken before surgery to make the tumors
glow under ultraviolet light
- Make sure the 5-ALA identifies tumor and not normal brain
- Make sure 5-ALA does not cause any side effects
Status | Terminated |
Enrollment | 6 |
Est. completion date | June 2016 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have clinically documented primary brain tumor for which resection is clinically indicated. Radiographic findings should be consistent with high grade glioma. Intraoperative frozen section should either be: anaplastic astrocytoma (WHO Grade III astrocytoma) or glioblastoma (WHO Grade IV astrocytoma). - Patients must be aged greater than 18 years old - Karnofsky Performance Score > 70 (Appendix) - Patients must have normal organ and marrow function as defined below: - Leukocytes > 3,000 /uL - Absolute neutrophil count > 1,500/uL - Platelets > 100,000/uL - Total bilirubin within normal institutional limits - AST/ALT within normal institutional limits - Creatinine within normal institutional limits Exclusion Criteria: - Prior craniotomy for resection, deep seated tumors in thalamus and brain stem. - History of allergic reactions to compounds of similar chemical composition to ALA. - Personal or family history of porphyrias - Personal history of hepatitis or other liver diseases. - Pregnant women are excluded from this study because ALA is of unknown teratogenic effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ALA, breastfeeding should be discontinued prior to treatment with ALA. - Inability to undergo magnetic resonance imaging (i.e. those patients with AICD/pacemakers). |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
United States | Johns Hopkins Hospital | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | serious adverse event (SAE) Rate | It will be considered as a serious adverse event with possible, probable, and definitely attribution to 5-ALA (SAE, detailed in section 8) if (within 2 weeks of dosing): Grade 1 or 2 LFT abnormalities not resolving within 2 weeks A single documented Grade 3 or 4 LFT abnormalities A Grade 3 or 4 skin photosensitivity |
2 weeks from dosing | Yes |
Secondary | Diagnostic Accuracy | The secondary objective of the study is to estimate sensitivity (true positive rate) and specificity (true negative rate); false positive rate and false negative rate; positive predict rate, and negative predict rate using a 5-ALA dose of 20 mg/kg to delineate tumor that may provide discrimination between normal and malignant tissue intra-operatively. | 72 hours post-operative | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
Not yet recruiting |
NCT00977327 -
Comparison of Neuro-navigational Systems for Resection-Control of Brain Tumors
|
N/A |